JPH07238026A - Arteriosclerosis inhibitor and food or medicine containing the same - Google Patents

Abstract

PURPOSE:To obtain the subject highly safe inhibitor having activity to improve blood lipid level balance, thus excellent in effect of inhibiting arteriosclerosis. CONSTITUTION:This arteriosclerosis inhibitor consisting of an extract from root of Astragalus huantchy. The extract can be obtained by the following processes: root of Astragalus huantchy, pref. its root rich in medicinal ingredient(s) is dried and cut into fine pieces, and then immersed in water and/or a polar organic solvent at room temperature for 1-3 days, or at the boiling point of the extraction solvent for 1-5hr, followed by, if needed, removing insolubles through filtration, or concentration under reduced pressures or by ultrafiltration and then evaporating the solvent to dryness. The extract can be pref. obtained by warm water extraction, filtration and then lyophilization. This inhibitor is used as a medicinal composition for treating circulatory diseases, or as a health food or functional food.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to an arteriosclerosis inhibitor, a food containing the same, or a pharmaceutical composition containing the same for treating cardiovascular diseases.

[0002]

2. Description of the Related Art In recent years, as westernization of eating habits has advanced,
The amount of fat intake per capita has continued to increase, and in particular, the increase in total fat intake in young people and the increase in animal fat intake in all age groups are remarkable. For this reason, excessive intake of fat may upset the balance of blood lipids or cause hyperlipidemia. Many of these people are triggered by adult diseases of the circulatory system such as arteriosclerosis, and the aging phenomenon of adult diseases of the circulatory system is caused, which is one of the major social problems.

In order to prevent such an increase in adult diseases of the circulatory system, it is necessary to improve the balance of blood lipids such as hyperlipidemia, which causes arteriosclerosis. Further, a method of ingesting a polyunsaturated fatty acid such as linoleic acid and a method of using chlorofibrate or nicotinic acid have been known.

However, ingestion of polyunsaturated fatty acids requires long-term continuous use, and there is a problem of excessive intake, chlorofibrate has side effects such as muscle cramps, and nicotinic acid also causes systemic flushing and gastrointestinal disorders. There was a problem that there were side effects.

[0005]

Accordingly, the present invention provides an arteriosclerosis inhibitor which has an effect of improving the balance of blood lipid levels, is excellent in the effect of suppressing arteriosclerosis, and is highly safe. An object of the present invention is to provide a food containing or a pharmaceutical composition for treating cardiovascular disease.

[0006]

In view of the above situation, the present inventors have collected herbal herbs, which have been used since ancient times and are considered to be safe for their use, and extract their extracts from arteries. As a result of extensive screening using the hardening inhibitory effect as an index, the inventors have found that the extract of Japanese cedar has an excellent arteriosclerosis suppressing effect and completed the invention.

Accordingly, the present invention relates to an arteriosclerosis inhibitor comprising an extract of Astragalus membranaceus.

The present invention also relates to a food containing the above arteriosclerosis inhibitor.

Furthermore, the present invention relates to a pharmaceutical composition for treating cardiovascular disease, which comprises the above arteriosclerosis inhibitor.

By the way, the Astragalus vulgaris used in the present invention is a Chinese herbal medicine based on a plant of the genus Astragalus of the legume family, Astragalus membranaceus (Astr.
agalusmemmbranaceus Bge.) and Astragalus mongolithus (Astragalus mongholicus Bge.), which have been widely used in China and Japan since ancient times as a herbal medicine. The medicinal effects in the Kampo medicine are water liquor, raw skin, stomach, etc., and nothing was known about the improvement of blood lipid balance and the arteriosclerosis inhibitory effect.

[0012] The above-mentioned Sugi (Cryptomeria japonica) contains a substance having an effect of improving the balance of the amount of lipids in blood, and it is possible to use crushed whole grass. It is preferably used as an active ingredient of the arteriosclerosis inhibitor of the present invention. Although the whole plant can be used as the plant part, roots rich in medicinal components are preferable. In the present invention, the extract refers to one or more selected from such pulverized products and extracts, the fractions described below, or concentrates thereof.

[0012] The extraction treatment of Astragalus sinensis is carried out by a continuous method, a batch method or the like, and is carried out by a conventional method by cold or hot digestion for an arbitrary time. For example, after the root of Astragalus membranaceus is dried, it is finely chopped and immersed in an extraction solvent at room temperature for 1 to 3 days or at the boiling temperature of the extraction solvent for 1 to 5 hours. At this time, as the extraction solvent used, water and polar organic solvents such as alcohols and acetones are preferable, and these may be used alone or in combination of two or more kinds. Then, if necessary, the insoluble matter may be removed by filtration, or the solvent may be dried and solidified by concentration under reduced pressure or ultrafiltration. A preferable one is a substance extracted with warm water, which is filtered and then freeze-dried. This substance is a light brown hygroscopic amorphous substance.

The extract thus obtained can be used as an arteriosclerosis inhibitor. This arteriosclerosis inhibitor may be directly prepared as a preparation, or may be mixed with various bases to prepare a preparation.

The blending amount and the type of base are not particularly limited, and may be appropriately set according to the dosage form. For example, pharmaceuticals include tablets, powders, granules, capsules and suppositories. , Injections, liquids and the like, and these may be formed into a dosage form according to a usual method together with a filler, an excipient, a lubricant, a disintegrant, a binder, a flavoring agent and the like.

As a food, as a general food, various food materials are added with a required amount of the extract and processed by an ordinary manufacturing method, and a healthy food, a plant or an extract as a functional food, The fractionated product can be used as it is or in a state in which it is easy to eat.

The daily dose of the above arteriosclerosis inhibitor in these compositions varies depending on the symptoms, height, weight, age, etc., but is 10 to 2000 mg per adult.
/ Kg, preferably 20 to 100 mg / Kg, may be administered once or in several divided doses.

Further, it is clear that the arteriosclerosis inhibitor of the present invention is superior in safety to the fact that Japanese cedar has been widely used as a herbal medicine since ancient times.

[0018]

The present invention will be described in more detail below with reference to examples, but it goes without saying that the present invention is not limited to these examples.

Example 1. Production Example 1. 1000 ml of purified water was added to 100 g of the shredded shrimp cut into a length of 5 to 10 mm, and the mixture was refluxed at 105 ° C. for 3 hours for extraction. After cooling, filtration was performed to obtain a filtrate, which was concentrated under reduced pressure and freeze-dried to obtain 23.8 g of an arteriosclerosis inhibitor as a brown amorphous substance.

Example 2. Production example 2. Purified water (500 ml) and ethanol (500 ml) were added to 100 g of shredded shrimp cut into a length of 5 to 10 mm, and the mixture was refluxed at 105 ° C. for 3 hours for extraction. After cooling, filtration was performed to obtain a filtrate, which was concentrated under reduced pressure and freeze-dried to obtain 18.4 g of an arteriosclerosis inhibitor.

Example 3. Acute toxicity and toxicity test An acute toxicity test by oral administration was carried out using 1 group of 10 ddy mice each having a body weight of 15 to 25 g. The sample used the arteriosclerosis inhibitor of Examples 1 and 2. 30 for each sample
% Saline solution, orally administered at 12 g / Kg, 72
After a lapse of time, life or death was judged. No deaths were observed in any of the groups. From this, it is clear that the arteriosclerosis inhibitor of the present invention is highly safe.

Example 4. Evaluation 1 of Arteriosclerosis Inhibitory Action The arteriosclerosis inhibitory effects of the arteriosclerosis inhibitor of Examples 1 and 2 were evaluated. That is, 5 per group of 10
A week-old ICR mouse was preliminarily bred for 4 weeks by freely ingesting a mixed solid feed of CE-2 (80%) manufactured by CLEA Japan and cellulose powder (20%) and water. Thereafter, the blank group as it is, mixed solid feed and water, and the control group, Example 1 administration group, and Example 2 administration group received CE-2 (80%) and lard (20%) high fat mixed solid feed and water. Allow free intake while at the same time 1 for control and blank groups
A weight% sodium carboxymethylcellulose aqueous solution was added to the Example 1 administration group and the Example 2 administration group, respectively.
1 containing 10% by weight of the arteriosclerosis inhibitor of Examples 1 and 2
A weight% aqueous sodium carboxymethylcellulose solution was orally administered at a dose of 0.5 ml / animal / day for 2 weeks.
After the administration, all mice were fasted for 16 hours and blood was collected. Serum was separated from the obtained blood by a conventional method, and the total cholesterol amount was measured by the enzyme method and the HDL cholesterol amount was measured by the heparin-Mn precipitation enzyme method. The value obtained by subtracting the amount of HDL cholesterol from the amount of total cholesterol and dividing this by the amount of HDL cholesterol was used as an arteriosclerosis index, and this value was used as an index of the arteriosclerosis suppressing action. The results are shown in Table 1. Here, * indicates a risk rate of less than 5% and ** indicates a risk rate of less than 1%, which indicates that there was a significant difference from the control group. From this, it is understood that the arteriosclerosis inhibitor of the present invention has an excellent arteriosclerosis inhibitory action.

[0023]

[Table 1]

Example 5. Mixing Example 1 for Candy: The following (A) component was heated and dissolved at 150 ° C., cooled to 120 ° C., then the (B) component was added, and after stirring, a uniform product was molded and cooled to give a candy. Obtained.

Example 6. Mixing Example 2 for Candy: The following component (A) is heated and dissolved at 150 ° C., cooled to 120 ° C., the component (B) is added, and after stirring, a uniform product is formed and cooled to give a candy. Obtained.

Example 7. Mixing example for gummy 1. The following component (A) is heated and dissolved at 110 ° C., the component (B) separately swollen and dissolved is added, and the component (C) is further added, and the mixture is poured into a mold and left for one day and night. Obtained.

Example 8. Mixing example with gummy 2. The following component (A) is heated and dissolved at 110 ° C., the component (B) separately swollen and dissolved is added, and the component (C) is further added, and the mixture is poured into a mold and left for one day and night. Obtained.

Example 9. Capsule The following component (A) is uniformly mixed and stirred, and then (B)
The ingredients were added and thoroughly kneaded with a kneader. This was encapsulated with a capsule filling machine to prepare a capsule.

Example 10. Tablet The following ingredients are mixed uniformly and granulated by the fluidized bed granulation method,
Dried. This was tableted with a tableting machine to obtain tablets. Dextrin 15 Lactose 5 Palatinose 15 Potato starch 40 Magnesium stearate 5 Arteriosclerosis inhibitor of Example 1 20

Example 11. Granules The following component (A) is placed in a glad granulator, and a 5% aqueous solution of component (B) is added dropwise to granulate, followed by drying at 40 ° C.
The particles were sized to obtain granules.

[0031]

INDUSTRIAL APPLICABILITY Since the agent for suppressing arterial effect of the present invention is highly safe and has an excellent effect for suppressing arterial effect, it is very useful for prevention and treatment of diseases of the circulatory system.

Claims (4)

[Claims] 1. An arteriosclerosis inhibitor comprising an extract of Astragalus sinensis. 2. The arteriosclerosis inhibitor according to claim 1 or 2, wherein the extract is extracted with water and / or a polar organic solvent. 3. A food containing the arteriosclerosis inhibitor according to claim 1. 4. A pharmaceutical composition for treating cardiovascular disease, which comprises the arteriosclerosis inhibitor according to claim 1.